Recombinant lymphotoxin
US6177543A · kind A · utility
0Cited by
5References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 19, 1998 |
| Grant date | Jan 23, 2001 |
| Priority date | — |
| Expiry date | Mar 19, 2018 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S930/143
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Biologically active lymphotoxin polypeptides are synthesized in recombinant cell culture. Novel nucleic acid and vectors incorporating same are provided. The compositions and processes herein enable the economical preparation of compositions containing uniform lymphotoxin polypeptides and variant lymphotoxins having amino acid sequences that differ from those found in nature. The lymphotoxins are purified to a specific activity of 2-10.times.10.sup.7 units/mg of protein by purification using a novel immobilized, lymphotoxin-neutralizing monoclonal antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.